Using Mission Bio's single-cell DNA sequencing technology, the center of excellence researchers revealed a co-occurrence of secondary driver mutations in cells carrying the KRAS (G12C) mutation, allowing them to circumvent and resist targeted therapy. This represents an important insight into one of the most promising new drugs in solid tumors.

Tapestri is the only commercial product capable of simultaneously analyzing DNA and other analytes like cell surface proteins at the single-cell level through its unique two-step droplet microfluidics technology, according to Mission Bio. Tapestri can be used to interrogate clonal mosaicism and neoplastic transition, clonal evolution, and metastatic dissemination with its ability to co-detect SNVs and CNVs at the single-cell level in a scalable manner.

As a tool for understanding disease resistance, users can detect rare emergent clones early with reliable and sensitive loss of heterozygosity measurements to understand how driver mutations are added over time that allows tumor escape and metastasis.

Mission Bio is a life sciences company that accelerates discoveries and cures for a wide range of diseases by equipping researchers with the tools they need to better measure and predict our resistance and response to new therapies.